Is Cost of Treatment the Main Barrier to Uptake of Retinoblastoma Treatment?

Authors

  • O. Fasina Department of Ophthalmology, University College Hospital/University of Ibadan, Ibadan.
  • A.O. Adeyemo Department of Ophthalmology, University College Hospital, Ibadan.
  • M.O. Ugalahi Department of Ophthalmology, University College Hospital/University of Ibadan, Ibadan.
  • B.A. Olusanya Department of Ophthalmology, University College Hospital/University of Ibadan, Ibadan.

Abstract

Introduction: Retinoblastoma is the commonest intraocular malignancy in childhood.1 It is treatable with survival rates of up to 90% in developed countries.2 Mortality rate is between 39-75% in some African/Asian countries largely due to late detection and insufficient healthcare measures. 3 Low treatment uptake has been reported in Nigeria, 4,5,6 and, high cost of treatment has been considered a significant barrier to treatment. 7,8,9 Other identified barriers to treatment include cost of transportation, inaccessibility to standard health institutions, fear of poor aesthetic outcome, patronage of alternative medicine, and scarcity of skilled human resources.10

Case Report: We report three patients with retinoblastoma whose parents abandoned their healthcare under a free treatment programme. They represent 50% of patients that presented for treatment during the period.

         Views | Downloads: 29 / 20

References

Ellsworth RM. Practical management of retinoblastoma. TransAm Ophthalmol Soc. 1969;67:462–534

Honavar SG, Singh AD, Shields CL, Meadows AT, Demirci H, Cater J, et al. Postenucleation adjuvant therapy in high risk retinoblastoma. Arch Ophthalmol 2002;120:923 31.

Desjardins L, Levy C, Lumbroso L, et al. (2000). Current treatment of retinoblastoma. 153 children treated between 1995 and 1998. J Fr Ophtalmol 23:475–481.

Bekibele CO, Ayede AI, Asaolu OO and Brown BJ. Retinoblastoma: The challenges of management in Ibadan, Nigeria. J Pediatr Hematol Oncol 2009; 31: 552-555

Abdu L and Malami S. Clinicopathological pattern and management of retinoblastoma in Kano, Nigeria. Ann Afr Med 2011;10: 214-219.

Musa KO, Aribaba OT, Oluleye TS, Olowoyeye AO and Akinsete AM. Challenges of retinoblastoma management in a Nigerian tertiary eye care facility. J Clin Sci 2017; 14: 182-187

Kumar A, Moulik NR, Mishra RK and Kumar D. Causes, outcome and prevention of abandonment in retinoblastoma in India. Pediatr Blood

Cancer 2013;60: 771 5.

Xunda Ji et al; Direct cost of retinoblastoma treatment during the first year of comprehensive therapy in China. Journal of Pediatric Ophthalmology and Strabismus. 2012; 49(6): 353-358

Aziz HA et al; Retinoblastoma treatment burden and economic cost: impart of age at diagnosis and selection of primary therapy. Clinical Ophthalmology (Auckland, NZ). 2012;6: 1601

Chawla B, Kumar K and Singh AD. Influence of socioeconomic and cultural factors on retinoblastoma management. Asia Pac J Oncol Nurs 2017; 4: 187-190.

Downloads

Published

2023-03-26

How to Cite

Fasina, O., Adeyemo, A., Ugalahi, M., & Olusanya, B. (2023). Is Cost of Treatment the Main Barrier to Uptake of Retinoblastoma Treatment?. Transactions of the Ophthalmological Society of Nigeria, 3(1). Retrieved from https://tosn.org.ng/index.php/home/article/view/178